

# CI Global Healthcare Leaders Index ETF

CBOE CANADA TICKER : CHCL.B

As of April 4, 2025 **CI Bio-Revolution Index ETF COMMON UNITS (CDNA)** merged into (CHCL.B)



AS AT DECEMBER 31, 2025


## FUND OVERVIEW

CHCL seeks to replicate, to the extent reasonably possible, the performance of a global healthcare index, net of expenses. Currently, CHCL seeks to replicate the performance of the Solactive Developed Markets Healthcare 150 CAD Index (CA NTR). The Index intends to track the performance of the largest 150 companies from the global healthcare industry.

## FUND DETAILS

Inception date	August 2021
Total net assets (\$CAD) As at 2025-12-31	<b>\$88.3 million</b>
NAVPS	<b>\$24.3385</b>
Market price	<b>\$24.5300</b>
MER (%) As at 2025-06-30	<b>0.37</b>
Management fee (%)	<b>0.35</b>
Units outstanding As at 2026-01-16	<b>3,631,800</b>
Asset class	<b>Sector Equity</b>
Currency	<b>CAD</b>
CUSIP	<b>12567E109</b>
Distribution frequency	<b>Quarterly</b>
Last distribution	<b>\$0.1025</b>

## Risk rating<sup>1</sup>




## INVESTOR SUITABILITY

For Those Who:


- Want Exposure To The Largest 150 Companies From The Global Healthcare Industry
- Are Investing For The Medium And/Or Long Term
- Can Tolerate Medium Risk

## PERFORMANCE<sup>2</sup>

Growth of \$10,000 (since inception date)



Calendar year performance



Average annual compound returns

YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception*
<b>9.58%</b>	<b>-2.51%</b>	<b>9.44%</b>	<b>15.08%</b>	<b>9.58%</b>	<b>6.68%</b>	<b>-</b>	<b>-</b>	<b>6.01%</b>

\*Since inception date

## DISTRIBUTION HISTORY<sup>3</sup>

Ex-Date	Total	Ex-Date	Total
2025-12-23	<b>0.1025</b>	2024-09-23	<b>0.0495</b>
2025-09-23	<b>0.0611</b>	2024-06-24	<b>0.1157</b>
2025-06-24	<b>0.1261</b>	2024-03-21	<b>0.0281</b>
2025-03-25	<b>0.0478</b>	2023-12-20	<b>0.1000</b>
2024-12-23	<b>0.0600</b>	2023-09-22	<b>0.0541</b>

## MANAGEMENT TEAM



CI Global Asset  
Management ETF

# CI Global Healthcare Leaders Index ETF

CBOE CANADA TICKER : CHCL.B

As of April 4, 2025 **CI Bio-Revolution Index ETF COMMON UNITS (CDNA)** merged into (CHCL.B)



AS AT DECEMBER 31, 2025

## PORTFOLIO ALLOCATIONS<sup>4</sup>

Asset allocation	(%)	Sector allocation	(%)	Geographic allocation	(%)
US Equity	<b>70.37</b>	Healthcare	<b>95.92</b>	United States	<b>70.37</b>
International Equity	<b>29.58</b>	Consumer Services	<b>1.96</b>	Switzerland	<b>8.74</b>
Cash and Equivalents	<b>0.04</b>	Consumer Goods	<b>1.66</b>	United Kingdom	<b>5.38</b>
Other	<b>0.01</b>	Industrial Goods	<b>0.41</b>	Japan	<b>3.72</b>
		Cash and Cash Equivalent	<b>0.04</b>	Other	<b>2.46</b>
		Other	<b>0.01</b>	France	<b>2.45</b>
				Denmark	<b>2.40</b>
				Ireland	<b>1.89</b>
				Germany	<b>1.52</b>
				Australia	<b>1.07</b>

## TOP HOLDINGS<sup>5</sup>

	Sector	(%)
1. Eli Lilly and Co	Drugs	<b>10.82%</b>
2. Johnson & Johnson	Drugs	<b>5.93%</b>
3. AbbVie Inc	Drugs	<b>4.80%</b>
4. UnitedHealth Group Inc	Healthcare Services	<b>3.55%</b>
5. Roche Holding AG - Partcptn	Drugs	<b>3.46%</b>
6. AstraZeneca PLC	Drugs	<b>3.31%</b>
7. Novartis AG CI N	Drugs	<b>3.13%</b>
8. Merck & Co Inc	Drugs	<b>3.13%</b>
9. Thermo Fisher Scientific Inc	Healthcare Equipment	<b>2.60%</b>
10. Abbott Laboratories	Healthcare Equipment	<b>2.58%</b>
11. Intuitive Surgical Inc	Healthcare Equipment	<b>2.40%</b>
12. Amgen Inc	Drugs	<b>2.09%</b>
13. Novo Nordisk A/S CI B	Drugs	<b>1.92%</b>
14. Gilead Sciences Inc	Drugs	<b>1.81%</b>
15. Danaher Corp	Healthcare Equipment	<b>1.74%</b>

Note: This page is not complete without disclaimers on the next page.

**Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. [Learn more at ci.com.](#)**

<sup>1</sup> The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

<sup>2</sup> Commissions, management fees and expenses all may be associated with an investment in exchange-traded funds (ETFs). You will usually pay brokerage fees to your dealer if you purchase or sell units of an ETF on recognized Canadian exchanges. If the units are purchased or sold on these Canadian exchanges, investors may pay more than the current net asset value when buying units of the ETF and may receive less than the current net asset value when selling them. Please read the prospectus before investing. Important information about an exchange-traded fund is contained in its prospectus. The indicated rates of return are the historical annual compounded total returns net of fees and expenses payable by the fund (except for figures of one year or less, which are simple total returns) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. ETFs are not guaranteed; their values change frequently, and past performance may not be repeated.

<sup>3</sup> Please refer to the fund's simplified prospectus for distribution information.

<sup>5</sup> The portfolio holdings are subject to change without notice and may only represent a small percentage of portfolio holdings. They are not recommendations to buy or sell any particular security.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

Certain statements contained in this communication are based in whole or in part on information provided by third parties and CI has taken reasonable steps to ensure their accuracy.

The rates of return are used only to illustrate the effects of the compound growth rate and are not intended to reflect future values or returns on investment in an investment fund.

The "Growth of \$10,000 invested" chart shows the final value of a hypothetical \$10,000 investment in securities in this class/series of the fund as at the end of the investment period indicated and is not intended to reflect future values or returns on investment in such securities.

Management Expense Ratio ("MER") represents the trailing 12-month management expense ratio, which reflects the cost of running the fund, inclusive of applicable taxes including HST, GST and QST (excluding commissions and other portfolio transaction costs) as a percentage of daily average net asset value the period, including the fund's proportionate share of any underlying fund(s) expenses, if applicable. The MER is reported in each fund's Management Report of Fund Performance ("MRFP"). MRFPs can be found within the Documents tab on ci.com.

The CI Exchange-Traded Funds (ETFs) are managed by CI Global Asset Management, a subsidiary of CI Financial Corp. CI Global Asset Management is a registered business name of CI Investments Inc.

© CI Investments Inc. 2026. All rights reserved.